logo
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

Miami Herald5 hours ago

Interim two-year follow-up data from 42 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit at 24 months compared to baseline
83% of subjects maintained a clinically meaningful benefit with a 3 or more point improvement in Revised Venous Clinical Severity Score (rVCSS)
9.1 point average rVCSS improvement among the clinically meaningful benefit cohort
Subjects experienced a median 74% improvement in leg pain
Interim follow-up data indicate sustained improvements across all venous-specific quality-of-life (QoL) indicators
A decision from the U.S. Food and Drug Administration (FDA) on the VenoValve is anticipated in the second half of 2025
Company to host live webcast with presenting Principal Investigator, today, June 6th at 11:20 AM ET / 10:20 AM CT - Access the Webcast Here
IRVINE, CA / ACCESS Newswire / June 6, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that interim two-year follow-up data on 42 subjects from the 75 person VenoValve U.S. pivotal trial will be presented today by lead enroller Dr. Cassius Iyad Ochoa Chaar, at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting (VAM25) being held June 4-7, 2025 in New Orleans, LA. Additionally, the Company announced it will host a live webcast to discuss these interim results today, Friday, June 6th at 11:20 AM ET / 10:20 AM CT (details below).
Key interim two-year follow-up data being presented at VAM25 include:
83.3% of subjects (n=35/42) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS).9.1 point average rVCSS improvement among the responder cohort.A median 74% improvement in leg pain, as measured by the Visual Analog Scale (VAS).Wound healing outcomes in 17 subjects with 25 ulcers showed that 60% of ulcers healed completely, 24% decreased in size, and 16% increased in size.Patient-reported outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym).Among the subjects (n=30), a 100% valve patency rate.
All values were calculated comparing each patient's baseline levels to the reported values at the patient's 24-month visit. The Revised Venous Clinical Severity Score (rVCSS) is a clinically validated scoring system used to track the progression or regression of venous diseases.
"These interim two-year follow-up data demonstrate substantial and sustained improvement across all effectiveness endpoints at two years. This is extremely encouraging, especially when you consider that all the patients enrolled in the study had severe CVI and failed all other treatment options," said Robert Berman, enVVeno Medical's Chief Executive Officer. "Despite attempts over many decades, nobody has been able to create an effective treatment for severe CVI caused by malfunctioning valves in the deep veins of the leg. The VenoValve has the potential to change the treatment paradigm for deep venous CVI, both for the millions of patients suffering from severe CVI and the thousands of vascular surgeons who have been waiting for an effective treatment option."
Dr. Cassius Iyad Ochoa Chaar, who is the Associate Professor of Surgery, Division of Vascular Surgery and Endovascular Therapy, Yale School of Medicine, will present the abstract titled, "Patients with Deep Venous Reflux Continue to Experience Clinical Improvement 2-year after Implantation of the VenoValve" today at VAM 2025.
The VenoValve is a potential first-in-class, surgical replacement venous valve for patients with severe deep venous CVI. The Company estimates that there are approximately 2.5 million potential new patients each year in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), with a decision anticipated in the second half of 2025.
Webcast Details
The Company will host a webcast presentation to discuss the results for investors, analysts and other interested parties today, June 6, 2025, at 11:20 AM ET / 10:20 AM CT. Joining enVVeno management for the event will be Dr. Chaar. The live webcast will be accessible on the Events page of the enVVeno website, envveno.com, and will be archived for 90 days.
About CVI
Severe, deep venous Chronic Venous Insufficiency (CVI) is a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg. When valves inside of the veins of the leg fail, blood flows in the wrong direction and pools in the lower leg, causing pressure within the veins of the leg to increase (venous hypertension). Symptoms of severe CVI include leg swelling, pain, edema, and in the most severe cases, recurrent open sores known as venous ulcers. The disease can severely impact everyday functions such as sleeping, bathing, dressing, and walking, and is known to result in high rates of depression and anxiety. There are currently no effective treatments for severe CVI of the deep vein system caused by valvular incompetence. Estimates indicate that CVI costs the U.S. healthcare system in excess of $4 billion each year.
About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease. The Company's lead product, the VenoValve®, is a first-in-class surgical replacement venous valve being developed for the treatment of deep venous Chronic Venous Insufficiency (CVI). The Company is also developing a non-surgical, transcatheter based replacement venous valve for the treatment of deep venous CVI called enVVe®. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the leg, and back to the heart and lungs. The VenoValve is currently being evaluated in the VenoValve U.S. pivotal study and the Company is currently performing the final testing necessary to seek approval for the pivotal trial for enVVe.
Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing (may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.
INVESTOR CONTACT:Jenene Thomas, JTC Team, LLCNVNO@jtcir.com(908) 824-0775
MEDIA CONTACT:Glenn Silver, FINN PartnersGlenn.Silver@finnpartners.com(973) 818-8198
SOURCE: enVVeno Medical Corporation

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Arya Resources Ltd. (RBZ) Upsizes Flow-Through Financing Amid Surging Investor Demand
Arya Resources Ltd. (RBZ) Upsizes Flow-Through Financing Amid Surging Investor Demand

Yahoo

time19 minutes ago

  • Yahoo

Arya Resources Ltd. (RBZ) Upsizes Flow-Through Financing Amid Surging Investor Demand

Vancouver, British Columbia--(Newsfile Corp. - June 9, 2025) - Arya Resources Ltd. (TSXV: RBZ) ("Arya" or the "Company") is pleased to announce upsizing of its previously announced flow-through financing, driven by growing investor interest. The Company will now issue 4,873,146 flow-through shares (the "FT Shares"), up from the originally planned 3,846,154 shares. The FT Shares are priced at $0.13 per share and qualify as "flow-through shares" as defined in subsection 66(15) of the Income Tax Act (Canada). The increase brings the total gross proceeds from the financing-including the non-flow-through tranche closed on June 3, 2025-to $1,143,509. This funding supports Arya's aggressive exploration and growth plans in one of Canada's most prospective mining jurisdictions. Use of Proceeds Flow-through proceeds will directly fund exploration work on Arya's Saskatchewan-based mineral projects, including its flagship Wedge Lake Gold Project, where the Company holds full permits to commence drilling as announced in its March 19, 2025 news release -see March 19, 2025 News Release. Non-flow-through proceeds will be allocated to general working capital, supporting ongoing corporate development and strategic initiatives. Finder's Fees In accordance with applicable securities laws and subject to TSX Venture Exchange approval, Arya may pay finder's fees to eligible parties as follows: 7% cash commission on subscription proceeds raised from introduced investors. Finder warrants equal to 7% of the securities sold to these investors, with terms identical to those of the investor warrants. About Arya Resources Ltd. (TSXV: RBZ)Arya Resources Ltd. is a Canadian-based mineral exploration company focused on unlocking the value of high-potential gold, silver, copper, nickel, and cobalt projects in mining-friendly jurisdictions. As a Tier-2 issuer on the TSX Venture Exchange, Arya is committed to building shareholder value through strategic acquisitions, targeted exploration, and sustainable development. On behalf of the Board of Directors: Rasool Mohammad, CEOEmail: rasool@ (604) 868-7737https:// Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. This news release includes "forward looking statements" that are subject to assumptions, risks and uncertainties. Statements in this news release which are not purely historical are forward looking statements, including without limitation any statements concerning the Company's intentions, plans, estimates, expectations or beliefs. Although the Company believes that any forward looking statements in this news release are reasonable, there can be no assurance that any such forward looking statements will prove to be accurate. The Company cautions readers that all forward looking statements, including without limitation those relating to the Company's future operations and business prospects, are based on assumptions, none of which can be assured, and are subject to certain risks and uncertainties that could cause actual events or results to differ materially from those indicated in the forward looking statements. Readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance on forward looking statements. Any forward looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward looking statements, or to update the reasons why actual events or results could or do differ from those projected in the forward looking statements. Except as required by law, the Company assumes no obligation to update any forward looking statements, whether as a result of new information, future events or otherwise. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Park Aerospace Corp. Declares Cash Dividend
Park Aerospace Corp. Declares Cash Dividend

Yahoo

time19 minutes ago

  • Yahoo

Park Aerospace Corp. Declares Cash Dividend

NEWTON, Kan., June 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Park Aerospace Corp. (NYSE-PKE) has declared a regular quarterly cash dividend of $0.125 per share payable August 1, 2025 to shareholders of record at the close of business on July 1, 2025. Park has paid 40 consecutive years of uninterrupted regular quarterly cash dividends, without ever skipping a dividend payment or reducing the amount of the dividend. The Company has paid $603.6 million in cash dividends, or $29.475 per share, since the beginning of the Company's 2005 fiscal year. Park Aerospace Corp. develops and manufactures solution and hot-melt advanced composite materials used to produce composite structures for the global aerospace markets. Park's advanced composite materials include film adhesives (Aeroadhere®) and lightning strike protection materials (Electroglide®). Park offers an array of composite materials specifically designed for hand lay-up or automated fiber placement (AFP) manufacturing applications. Park's advanced composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as 'drones'), business jets, general aviation aircraft and rotary wing aircraft. Park also offers specialty ablative materials for rocket motors and nozzles and specially designed materials for radome applications. As a complement to Park's advanced composite materials offering, Park designs and fabricates composite parts, structures and assemblies and low volume tooling for the aerospace industry. Target markets for Park's composite parts and structures (which include Park's proprietary composite SigmaStrut™ and AlphaStrut™ product lines) are, among others, prototype and development aircraft, special mission aircraft, spares for legacy military and civilian aircraft and exotic spacecraft. Park's objective is to do what others are either unwilling or unable to do. When nobody else wants to do it because it is too difficult, too small or too annoying, sign us up. Additional corporate information is available on the Company's website at Contact: Donna D'Amico-Annitto 486 North Oliver Road, Bldg. ZNewton, Kansas 67114(316) 283-6500Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

How to buy the Nintendo Switch 2: Current stock availability for consoles and accessories
How to buy the Nintendo Switch 2: Current stock availability for consoles and accessories

Engadget

time38 minutes ago

  • Engadget

How to buy the Nintendo Switch 2: Current stock availability for consoles and accessories

You can finally buy the Nintendo Switch 2 in the US — or rather, try to buy. The $450 console officially went up for sale at midnight ET on June 5, and several retailers have offered the device both online and in-store in the days since. That said, online stock dried up fairly quickly at most stores last week and remains highly limited as of Monday morning. Walmart briefly resumed sales late Friday night, and you may be able to grab a bundle at Costco if you're a member there, but it's slim pickings beyond that as of this writing. Wider restocks will happen at some point, though exact timing isn't clear. Broadly speaking, people had a bit more luck on launch week by venturing to a physical retail store. We can't guarantee you'll still be able to snag a Switch 2 the old-fashioned way, but it's worth checking if a local Target, Best Buy, Walmart or GameStop — the four official retailers Nintendo lists on its store page — still has consoles in stock. Either way, if you're still on the hunt, we've rounded up all of the latest information we could find on how to buy the Nintendo Switch 2 and where you can pick one up. Walmart opened up online purchases at midnight ET on June 5, but the console alone and Nintendo's Mario Kart World bundle are out of stock as our latest update. Both SKUs briefly returned around 11:30PM ET on June 6, but we haven't seen much since then. Naturally, the world's largest retailer is also selling the console at its brick-and-mortar locations, though the company has noted that quantities are limited and inventory will vary by location. Target began selling the Switch 2 in stores on June 5, then restocked its online inventory for at least a couple of hours starting around 3:30AM ET on June 6. It appears to be fully out of stock as we write this, but again you should still look into the locations closest to you for in-store availability just to be safe. GameStop has advertised in-store availability, though exactly how much stock your local store may have will vary by location. Online, the device has been unavailable for most of the past few days. We've seen a $625 bundle that includes Mario Kart World , a microSD Express card and a few other accessories pop up a bit more frequently than the standard SKUs, though it's sold out now (and kind of a raw deal anyway). Still, it may be one to bookmark if you can stomach the extra cost. The listings for the base console and Mario Kart bundle, meanwhile, now point to a "Find a Store" page. Best Buy said it'd have limited stock at its retail locations starting June 5. It previously confirmed it would not sell the console online during launch week, however, and that remains the case as of Monday morning. You may still have some luck at certain membership-based retailers. A Mario Kart World bundle at Costco that includes a 12-month Switch Online subscription has gone in and out of stock since Thursday morning. Sam's Club has had a bundle without the Switch Online sub as well, though it's out of stock at the moment. We also saw the console at BJ's early on June 5, but it's not live there now. Verizon briefly had the Switch 2 available on Thursday morning, but that's dried up, and only those with Verizon service were able to order. Amazon hasn't had any form of Switch 2 listing on its website thus far, nor has it listed first-party Switch 2 games like Mario Kart World . The company didn't take pre-orders for the Switch 2 either, so it's unclear if and when it will sell the device. Newegg has listed the Switch 2 on its site for several weeks, but it's given no indication as to when it'll begin sales. It's currently showing a couple listings from a third-party seller, but the prices there are massively overinflated, so you should ignore them. With all of these stores, we've seen the Mario Kart World bundle available in greater quantities online than the base console, which costs $50 less. But given that Mario Kart is the Switch 2's biggest launch game and retails for $80 on its own, that may not be the worst thing. Nintendo, meanwhile, is only offering the Switch 2 via an invite system. This requires you to have been a Switch Online member for at least 12 months and logged at least 50 hours of Switch 1 playtime as of April 2. It can't hurt to sign up if you meet the criteria, but don't expect it to bear fruit immediately — many people who registered in April still haven't received an invite. You can find a list of every Switch 2 retail listing we could find below. Just be aware that this is meant to be a reference, not a rundown of everywhere the device is available right this second. Where to buy Switch 2 + Mario Kart World bundle: Where to buy Switch 2: Nintendo is selling a number of Switch 2 accessories alongside the console, from controllers to cases to cameras for the new GameChat feature. Most of these became available on June 5 as well. The same goes for games like Mario Kart World and the Switch 2 version of The Legend of Zelda: Tears of the Kingdom . Another big Switch 2 release, Donkey Kong Bananza , won't be available until mid-July but is still up for pre-order now. As of Monday morning, just about all Switch 2 games remain widely available. Stock for the accessories is a little spottier, but most devices are still available at multiple retailers. Nintendo's official Switch 2 carrying cases are the main exceptions right now, so you may need to look to third-party alternatives if you want some protection for your console right away. Mario Kart World ($80) Nintendo Walmart GameStop Best Buy Target Donkey Kong Bananza ($70) Nintendo Walmart GameStop Best Buy Target Costco (membership required) Additional Switch 2 games Nintendo Amazon Walmart GameStop Best Buy Target Samsung microSD Express Card (256GB) for Nintendo Switch 2 ($60) Nintendo Walmart GameStop Best Buy Target Amazon Joy-Con 2 bundle ($95) Nintendo Walmart GameStop Best Buy Target Switch 2 Pro Controller ($85) Switch 2 Camera ($55) Nintendo Walmart GameStop Best Buy Target Hori Nintendo Switch 2 Piranha Plant Camera ($60) Joy-Con 2 Charging Grip ($40) Nintendo Walmart GameStop Best Buy Target Joy-Con 2 Wheels (set of 2) ($25) Nintendo Walmart GameStop Best Buy Target Switch 2 All-in-One Carrying Case ($85) Nintendo Walmart GameStop Best Buy Target Switch 2 Carrying Case and Screen Protector ($40) Nintendo (invite required) Walmart GameStop Best Buy Target Nintendo Switch 2 Dock Set ($120)

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store